Literature DB >> 29671162

GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better?

Linda A Feagins1,2, Rick A Weideman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29671162     DOI： 10.1007/s10620-018-5060-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  13 in total

1.  Dabigatran and postmarketing reports of bleeding.

Authors:  Mary Ross Southworth; Marsha E Reichman; Ellis F Unger
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

2.  Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.

Authors:  Mark M Brodie; Jill C Newman; Tyler Smith; Don C Rockey
Journal:  Am J Med       Date:  2017-11-22       Impact factor: 4.965

3.  Dabigatran: how the drug company withheld important analyses.

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2014-07-23

4.  National Trends in Ambulatory Oral Anticoagulant Use.

Authors:  Geoffrey D Barnes; Eleanor Lucas; G Caleb Alexander; Zachary D Goldberger
Journal:  Am J Med       Date:  2015-07-02       Impact factor: 4.965

5.  A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.

Authors:  David J Cangemi; Timothy Krill; Rick Weideman; Daisha J Cipher; Stuart J Spechler; Linda A Feagins
Journal:  Am J Gastroenterol       Date:  2017-02-28       Impact factor: 10.864

6.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.

Authors:  Jennifer M Kolb; Kathryn Friedman Flack; Prapti Chatterjee-Murphy; Jay Desai; Lars C Wallentin; Michael Ezekowitz; Stuart Connolly; Paul Reilly; Martina Brueckmann; John Ilgenfritz; James Aisenberg
Journal:  Dig Dis Sci       Date:  2018-03-27       Impact factor: 3.199

9.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

10.  Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

Authors:  Neena S Abraham; Sonal Singh; G Caleb Alexander; Herbert Heien; Lindsey R Haas; William Crown; Nilay D Shah
Journal:  BMJ       Date:  2015-04-24
View more
  2 in total

1.  Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System.

Authors:  Annamaria Mascolo; Rosanna Ruggiero; Maurizio Sessa; Cristina Scavone; Liberata Sportiello; Concetta Rafaniello; Francesco Rossi; Annalisa Capuano
Journal:  Front Pharmacol       Date:  2019-04-30       Impact factor: 5.810

2.  Major gastrointestinal bleeding and antithrombotics: Characteristics and management.

Authors:  Jacques Bouget; Damien Viglino; Quentin Yvetot; Emmanuel Oger
Journal:  World J Gastroenterol       Date:  2020-09-28       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.